The Hindu Business Line : Sun Pharma Q4 net rises 34%

Mumbai May 18 Sun Pharmaceutical Industries Ltd has posted a 34.32 per cent growth in net profit after tax, at Rs 155.67 crore for the quarter ended March 31. This stands compared to Rs 115.89 crore for the quarter ended March 31, 2006. Total income (net of excise) increased to Rs 633.74 crore (Rs 454.53 crore).

The company posted a profit after tax of Rs 628.93 crore (Rs 461.29 crore) for the year ended March 31. Total income (net of excise) increased to Rs 2,404.05 crore (Rs 1,805.12 crore).

According to Mr Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, "The demerger of our R&D (research and development) programmes for NCE (new chemical entities) and NDDS (new drug delivery systems) into a new company will help reinforce the focus with which we've always run our core business. This move positions us to strongly participate in the excellent potential that exists for generics, worldwide." Group results

The group posted a net profit of Rs 212.08 crore for the quarter ended March 31, 2007, up 48.39 per cent as compared to Rs 142.92 crore for the quarter ended March 31, 2006. Total income (net of excise) has increased to Rs 638.37 crore (Rs 482.12 crore).

It posted a net profit of Rs 774.08 crore (Rs 573.25 crore) for the year ended March 31, 2007. Total income (net of excise) has increased to Rs 2,357.34 crore (Rs 1,803.35 crore).

More Stories on : Pharmaceuticals | Sun Pharmaceutical Industries Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
$1.5-b revenue lifts Dr Reddy's to the top slot

Sun Pharma Q4 net rises 34%

PowerGrid net rises 22%

Tata Motors net rises 26% in Q4

Max India reports loss in fourth quarter

Federal Bank full-year net rises 30%